1. Verastem Oncology will present at Jefferies Global Healthcare Conference. 2. The event promotes engagement with investors and stakeholders. 3. Verastem focuses on RAS/MAPK pathway-driven cancer therapies. 4. The upcoming discussion may enhance visibility and investor interest in VSTM. 5. AVMAPKI™ and FAKZYNJA™ are currently marketed in the U.S.
Increased visibility at major conferences can boost investor confidence and interest, similar to how previous conference presentations have positively influenced stock prices.
The announcement fosters investor engagement and could positively influence VSTM’s stock performance.
Investor sentiment and stock price may experience immediate fluctuations due to conference engagement, leading to short-term opportunities.
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York.
A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company’s website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.